Dr. Georgios E. Manousakis, MD

Dr. Manousakis practices at M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview.

Dr. Manousakis' NPI, 1588854608, was assigned on July 25, 2007. Dr. Manousakis holds Minnesota license 55369.

Dr. Manousakis' primary practice is M Health Fairview University of Minnesota Medical Center, at 2450 Riverside Avenue, Minneapolis, MN 55454 in Hennepin County. The practice phone is (612) 624-1765.

Dr. Manousakis' primary practice is M Health Fairview University of Minnesota Medical Center in Minneapolis, Minnesota, part of M Health Fairview. Dr. Manousakis is also affiliated with M Health Fairview Southdale Hospital. The medical group on file is M Health Fairview Recovery Clinic. Dmand AI also links Dr. Manousakis to 3 more hospitals, 3 group practices and clinics, 3 medical groups, 1 dialysis center and 1 ambulatory surgery center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Manousakis practices, 10 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Manousakis' primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Manousakis is licensed in Minnesota.

CMS data shows 599 Medicare services from Dr. Manousakis across 12 procedure codes in 2024, for 250 Medicare patients. Medicare paid $40,627 for them. Every service was in an office.

CMS counts 250 Medicare patients who saw Dr. Manousakis in 2024. The largest group is 65 to 74, with 101 patients. 65% of them have high blood pressure, and 65% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.05, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Manousakis' median patient age at 66, with 56% women.

In 2024, Dr. Manousakis wrote 906 Medicare Part D claims for 158 patients. 86% of them were for generic drugs. CMS names the drug for 758 of them, across 18 drugs with 11 or more claims each, at $1,121,826 in total drug cost. In 2023, CMS named 701 claims across 17 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Manousakis for performance year 2024, reported as part of a group. Dr. Manousakis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Manousakis as offering telehealth.

Dmand AI links 27 papers to Dr. Manousakis, published from 2010 to 2023. 2020 was the busiest year, with 6. The most frequent topics are Amyotrophic Lateral Sclerosis, Disease Progression and Electromyography. Dr. Manousakis has published most often in Muscle Nerve. Dr. Manousakis' most frequent co-authors are David Walk, MD, Malik Ya Ghannam, MD and Matthew B. Harms, MD.

Dmand AI links Dr. Manousakis to 3 clinical trials, 2 of them phase 2 studies. Conditions studied include Muscular Dystrophies, Amyotrophic Lateral Sclerosis and Muscular Dystrophy, Duchenne.

CMS Open Payments shows 14 general payments to Dr. Manousakis from 4 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 91% of the total. Alexion Pharmaceuticals, Inc. paid the most, $7,500.